3.3 Impact of drugs on the prevalence of COVID-19
Drugs used by patients with ARDs impact the infection of COVID-19(Figure p4). The regression analysis showed that anti-rheumatic medication did not contribute to the risk of COVID-19(Figure p5 and p6). From the perspective of the primary drugs, the prevalence of ARD patients mainly using GC, bDMARDs, csDMARDs, and anti-TNF therapy was 0.088(95%CI:0.065-0.110), 0.041(95%CI:0.031-0.051), 0.055(95%CI:0.043-0.067) and 0.029(95%CI:0.003-0.056), respectively(Figure 3). Patients mainly using GC had the highest prevalence, and those using anti-TNF therapy had the lowest prevalence.